Limited-Stage Hodgkin Lymphoma: Minimizing Toxicity

Limited-Stage Hodgkin Lymphoma: Minimizing Toxicity

Early-stage classic Hodgkin lymphoma has been highly curable using extended-field radiation therapy (RT) alone, combined-modality therapy consisting of chemotherapy and RT, and more recently chemotherapy alone. Radiation therapy either to an extended field (extended-field RT) or to various iteration...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:The cancer journal (Sudbury, Mass.) Mass.), 2018-09, Vol.24 (5), p.223-229
1. Verfasser: Straus, David J
Format: Artikel
Sprache:eng
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 229
container_issue 5
container_start_page 223
container_title The cancer journal (Sudbury, Mass.)
container_volume 24
creator Straus, David J
description Early-stage classic Hodgkin lymphoma has been highly curable using extended-field radiation therapy (RT) alone, combined-modality therapy consisting of chemotherapy and RT, and more recently chemotherapy alone. Radiation therapy either to an extended field (extended-field RT) or to various iterations of an involved field (involved-field RT) is potentially associated with late morbidity and mortality, particularly second primary cancers and cardiovascular complications. Treatment with chemotherapy alone, when possible, can achieve a high cure rate while avoiding these risks. This review describes the evolution of treatment for early-stage classic Hodgkin lymphoma.
doi_str_mv 10.1097/PPO.0000000000000329
format Article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2111743744</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2111743744</sourcerecordid><originalsourceid>FETCH-LOGICAL-c256t-3571ec31af822e03de40408625e648a946b5e01c0813fa208f80e6b2306866083</originalsourceid><addsrcrecordid>eNpdkE1Lw0AQhhdRbK3-A5EcvaTOfmR3402KWiHSghW8LdtkElebD7MpWH-9Ka0izmXm8LwzzEPIOYUxhVhdzeezMfwtzuIDMqSRgJBz-XK4nZkOY0rVgJx4_wZAlVJwTAYcmFAsUkPCE1e6DrPwqbMFBtM6K95dFSSbsnmtS3sdPLqqJ75cVQSL-tOlrtuckqPcrjye7fuIPN_dLibTMJndP0xukjBlkexCHimKKac214wh8AwFCNCSRSiFtrGQywiBpqApzy0DnWtAuWQcpJYSNB-Ry93epq0_1ug7Uzqf4mplK6zX3jDavya4EqJHxQ5N29r7FnPTtK607cZQMFtdptdl_uvqYxf7C-tlidlv6McP_wYoYWLV</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2111743744</pqid></control><display><type>article</type><title>Limited-Stage Hodgkin Lymphoma: Minimizing Toxicity</title><source>Journals@Ovid Complete</source><creator>Straus, David J</creator><creatorcontrib>Straus, David J</creatorcontrib><description>Early-stage classic Hodgkin lymphoma has been highly curable using extended-field radiation therapy (RT) alone, combined-modality therapy consisting of chemotherapy and RT, and more recently chemotherapy alone. Radiation therapy either to an extended field (extended-field RT) or to various iterations of an involved field (involved-field RT) is potentially associated with late morbidity and mortality, particularly second primary cancers and cardiovascular complications. Treatment with chemotherapy alone, when possible, can achieve a high cure rate while avoiding these risks. This review describes the evolution of treatment for early-stage classic Hodgkin lymphoma.</description><identifier>ISSN: 1528-9117</identifier><identifier>EISSN: 1540-336X</identifier><identifier>DOI: 10.1097/PPO.0000000000000329</identifier><identifier>PMID: 30247257</identifier><language>eng</language><publisher>United States</publisher><ispartof>The cancer journal (Sudbury, Mass.), 2018-09, Vol.24 (5), p.223-229</ispartof><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><cites>FETCH-LOGICAL-c256t-3571ec31af822e03de40408625e648a946b5e01c0813fa208f80e6b2306866083</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780,27901,27902</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/30247257$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Straus, David J</creatorcontrib><title>Limited-Stage Hodgkin Lymphoma: Minimizing Toxicity</title><title>The cancer journal (Sudbury, Mass.)</title><addtitle>Cancer J</addtitle><description>Early-stage classic Hodgkin lymphoma has been highly curable using extended-field radiation therapy (RT) alone, combined-modality therapy consisting of chemotherapy and RT, and more recently chemotherapy alone. Radiation therapy either to an extended field (extended-field RT) or to various iterations of an involved field (involved-field RT) is potentially associated with late morbidity and mortality, particularly second primary cancers and cardiovascular complications. Treatment with chemotherapy alone, when possible, can achieve a high cure rate while avoiding these risks. This review describes the evolution of treatment for early-stage classic Hodgkin lymphoma.</description><issn>1528-9117</issn><issn>1540-336X</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2018</creationdate><recordtype>article</recordtype><recordid>eNpdkE1Lw0AQhhdRbK3-A5EcvaTOfmR3402KWiHSghW8LdtkElebD7MpWH-9Ka0izmXm8LwzzEPIOYUxhVhdzeezMfwtzuIDMqSRgJBz-XK4nZkOY0rVgJx4_wZAlVJwTAYcmFAsUkPCE1e6DrPwqbMFBtM6K95dFSSbsnmtS3sdPLqqJ75cVQSL-tOlrtuckqPcrjye7fuIPN_dLibTMJndP0xukjBlkexCHimKKac214wh8AwFCNCSRSiFtrGQywiBpqApzy0DnWtAuWQcpJYSNB-Ry93epq0_1ug7Uzqf4mplK6zX3jDavya4EqJHxQ5N29r7FnPTtK607cZQMFtdptdl_uvqYxf7C-tlidlv6McP_wYoYWLV</recordid><startdate>201809</startdate><enddate>201809</enddate><creator>Straus, David J</creator><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>201809</creationdate><title>Limited-Stage Hodgkin Lymphoma: Minimizing Toxicity</title><author>Straus, David J</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c256t-3571ec31af822e03de40408625e648a946b5e01c0813fa208f80e6b2306866083</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2018</creationdate><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Straus, David J</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>The cancer journal (Sudbury, Mass.)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Straus, David J</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Limited-Stage Hodgkin Lymphoma: Minimizing Toxicity</atitle><jtitle>The cancer journal (Sudbury, Mass.)</jtitle><addtitle>Cancer J</addtitle><date>2018-09</date><risdate>2018</risdate><volume>24</volume><issue>5</issue><spage>223</spage><epage>229</epage><pages>223-229</pages><issn>1528-9117</issn><eissn>1540-336X</eissn><abstract>Early-stage classic Hodgkin lymphoma has been highly curable using extended-field radiation therapy (RT) alone, combined-modality therapy consisting of chemotherapy and RT, and more recently chemotherapy alone. Radiation therapy either to an extended field (extended-field RT) or to various iterations of an involved field (involved-field RT) is potentially associated with late morbidity and mortality, particularly second primary cancers and cardiovascular complications. Treatment with chemotherapy alone, when possible, can achieve a high cure rate while avoiding these risks. This review describes the evolution of treatment for early-stage classic Hodgkin lymphoma.</abstract><cop>United States</cop><pmid>30247257</pmid><doi>10.1097/PPO.0000000000000329</doi><tpages>7</tpages></addata></record>
fulltext fulltext
identifier ISSN: 1528-9117
ispartof The cancer journal (Sudbury, Mass.), 2018-09, Vol.24 (5), p.223-229
issn 1528-9117
1540-336X
language eng
recordid cdi_proquest_miscellaneous_2111743744
source Journals@Ovid Complete
title Limited-Stage Hodgkin Lymphoma: Minimizing Toxicity
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-01T15%3A52%3A37IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Limited-Stage%20Hodgkin%20Lymphoma:%20Minimizing%20Toxicity&rft.jtitle=The%20cancer%20journal%20(Sudbury,%20Mass.)&rft.au=Straus,%20David%20J&rft.date=2018-09&rft.volume=24&rft.issue=5&rft.spage=223&rft.epage=229&rft.pages=223-229&rft.issn=1528-9117&rft.eissn=1540-336X&rft_id=info:doi/10.1097/PPO.0000000000000329&rft_dat=%3Cproquest_cross%3E2111743744%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2111743744&rft_id=info:pmid/30247257&rfr_iscdi=true